Broncus has announced that the company's thermal vapour treatment system InterVapor has been granted approval by the National Medical Products Administration of China (NMPA), denoting the official commercialisation of the world's only such product in China. This is the first NMPA-approved thermal vapour energy ablation systems in China and in the world for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and it is the only minimally invasive interventional lung volume reduction product that can achieve sequential staged treatment targeting the lung segment level, thereby leading to a new era of interventional pulmonary in China.

InterVapor is the first thermal vapor energy ablation system in China approved for Priority Approval for the treatment of COPD. It is a medical device that is needed imminently in clinics and no similar product has been approved in China. InterVapor is also safe and effective for patients with complete or incomplete fissure, and offers a solution with minimal invasion and disruption for patients with advanced COPD. The company has obtained an exclusive patent for the use of thermal vapour for pulmonary treatments with a state-of-the-art technology. 

InterVapor can transport thermal vapour to the targeted lung segment through the bronchial pathway, and deliver energy through air convection, breaking through the original obstacles of energy transmission such as high air content in the lungs, and treating severely diseased lung segments, significantly improving the quality of life of patients and lung function and their exercise tolerance while preserving more healthy lung tissues.